New generation estrogen receptor-targeted agents in breast cancer: present situation and future prospectives

Endocrine therapy that blocks estrogen receptor signaling has been effective for decades as a primary treatment choice for breast cancer patients expressing the estrogen receptor. However, the issue of drug resistance poses a significant clinical challenge. It is therefore critically important to cr...

Full description

Saved in:
Bibliographic Details
Main Authors: Jian Min, Xin Liu, Rouming Peng, Chun-Chi Chen, Wei Wang, Rey-Ting Guo
Format: Article
Language:English
Published: Compuscript Ltd 2024-02-01
Series:Acta Materia Medica
Online Access:https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2024-0006
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849421602724249600
author Jian Min
Xin Liu
Rouming Peng
Chun-Chi Chen
Wei Wang
Rey-Ting Guo
author_facet Jian Min
Xin Liu
Rouming Peng
Chun-Chi Chen
Wei Wang
Rey-Ting Guo
author_sort Jian Min
collection DOAJ
description Endocrine therapy that blocks estrogen receptor signaling has been effective for decades as a primary treatment choice for breast cancer patients expressing the estrogen receptor. However, the issue of drug resistance poses a significant clinical challenge. It is therefore critically important to create new therapeutic agents that can suppress ERα activity, particularly in cases of ESR1 mutations. This review highlights recent efforts in drug development of next generation ER-targeted agents, including oral selective ER degraders, proteolysis-targeting chimera ER degraders, and other innovative molecules, such as complete estrogen receptor antagonists and selective estrogen receptor covalent antagonists. The drug design, efficacy, and clinical trials for each compound are detailed herein.
format Article
id doaj-art-a720e144bdbd48b290ccb3685f9b95a3
institution Kabale University
issn 2737-7946
language English
publishDate 2024-02-01
publisher Compuscript Ltd
record_format Article
series Acta Materia Medica
spelling doaj-art-a720e144bdbd48b290ccb3685f9b95a32025-08-20T03:31:24ZengCompuscript LtdActa Materia Medica2737-79462024-02-0131577110.15212/AMM-2024-0006New generation estrogen receptor-targeted agents in breast cancer: present situation and future prospectivesJian MinXin LiuRouming PengChun-Chi ChenWei WangRey-Ting GuoEndocrine therapy that blocks estrogen receptor signaling has been effective for decades as a primary treatment choice for breast cancer patients expressing the estrogen receptor. However, the issue of drug resistance poses a significant clinical challenge. It is therefore critically important to create new therapeutic agents that can suppress ERα activity, particularly in cases of ESR1 mutations. This review highlights recent efforts in drug development of next generation ER-targeted agents, including oral selective ER degraders, proteolysis-targeting chimera ER degraders, and other innovative molecules, such as complete estrogen receptor antagonists and selective estrogen receptor covalent antagonists. The drug design, efficacy, and clinical trials for each compound are detailed herein.https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2024-0006
spellingShingle Jian Min
Xin Liu
Rouming Peng
Chun-Chi Chen
Wei Wang
Rey-Ting Guo
New generation estrogen receptor-targeted agents in breast cancer: present situation and future prospectives
Acta Materia Medica
title New generation estrogen receptor-targeted agents in breast cancer: present situation and future prospectives
title_full New generation estrogen receptor-targeted agents in breast cancer: present situation and future prospectives
title_fullStr New generation estrogen receptor-targeted agents in breast cancer: present situation and future prospectives
title_full_unstemmed New generation estrogen receptor-targeted agents in breast cancer: present situation and future prospectives
title_short New generation estrogen receptor-targeted agents in breast cancer: present situation and future prospectives
title_sort new generation estrogen receptor targeted agents in breast cancer present situation and future prospectives
url https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2024-0006
work_keys_str_mv AT jianmin newgenerationestrogenreceptortargetedagentsinbreastcancerpresentsituationandfutureprospectives
AT xinliu newgenerationestrogenreceptortargetedagentsinbreastcancerpresentsituationandfutureprospectives
AT roumingpeng newgenerationestrogenreceptortargetedagentsinbreastcancerpresentsituationandfutureprospectives
AT chunchichen newgenerationestrogenreceptortargetedagentsinbreastcancerpresentsituationandfutureprospectives
AT weiwang newgenerationestrogenreceptortargetedagentsinbreastcancerpresentsituationandfutureprospectives
AT reytingguo newgenerationestrogenreceptortargetedagentsinbreastcancerpresentsituationandfutureprospectives